Perioperative Management of Tumor Necrosis Factor Alpha Inhibitors

VernacularTitle:肿瘤坏死因子α抑制药的围手术期管理
Author: Mengdi SHENG ¹ ; Han XIE ; Xudong MA ; Haixia ZHANG ; Li LI
Author Information

1. 中国药科大学南京鼓楼医院药学部,南京 210008
Keywords: Tumor necrosis factor alpha inhibitor; Perioperative; Rheumatoid arthritis; Ankylosing spondylitis; Inflammatory bowel disease; Psoriasis
From: Herald of Medicine 2024;43(9):1434-1439
CountryChina
Language:Chinese
Abstract: Tumor necrosis factor alpha inhibitors(TNFαi)are a class of biological agents that suppress the immune system and lower inflammatory levels,and they are increasingly employed to treat autoimmune diseases.However,TNFαi theoretically can increase the risk of infection,tumor,and other complications.To increase the safety of perioperative medicine,it is necessary to balance the relative risks of increased complication rates due to continuous medication and symptom aggravation due to medication suspension for patients undergoing surgery.Currently,there is no comprehensive clinical guideline for the perioperative management of TNFαi in China.To provide a reference for the perioperative management of TNFαi,this article used the indications of rheumatoid arthritis,ankylosing spondylitis,inflammatory bowel disease,and psoriasis as its starting point to systematically sort out the recommendations and considerations for the use of TNFαi in the perioperative drug treatment of patients.